Company

Themis has a developed a sophisticated vaccine platform and pipeline based on advanced understanding of immune system mechanisms. Initially focused on preventing infectious diseases, the Company has demonstrated the speed and potential of the platform through its world-leading Phase 2 clinical development program for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading EU-based VCs, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and manufacturing capabilities to diseases with high market potential both alone and for its partners.